The anti-tumor functions of the first-in-class MOv18 IgE have been previously reported, and point to the involvement of IgE in engaging and reprogramming Fcε receptor-expressing immune effector cells, such as monocytes and macrophages, in the tumor microenvironment (TME)11–13,15,30,31. This evidence concerns the gene IGHE and neoplasm.